Call for proposals to support innovative manufacturing technologies and processes in the Union for medicines production (HERA) - CP-g-24-12

0 保存 · 0 分享 · 0 评论参与讨论

资助机构

EU4 Health Programme (EU4H)

European Commission

截止日期

2024-09-05

基金规模

€17000000

申请资格

Conditions

1. Admissibility conditions: described in section 5 of the call document

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System

2. Eligible countries: described in section 6 of of the call document

3. Other eligibility conditions: described in section 6 of the call document

4. Financial and operational capacity and exclusion: described in section 7 of the call document

5. Evaluation and award:

Award criteria, scoring and thresholds: described in section 9 of the call document

Submission and evaluation processes: described section 8 of the call document and the Online Manual

Indicative timeline for evaluation and grant agreement: described in section 4 of the call document

6. Legal and financial set-up of the grants: described in section 10 of the call document

Documents

Call documents:

Call document

Standard application form ([ToA])

Detailed budget table ([ToA])

EU4Health Programme General MGA v1.1

EU4Health Work Programme 2024

EU4Health Regulation 2021/522

EU Financial Regulation 2018/1046

基金编号

EU4H-2024-PJ-01-3

说明

Objective:

This action aims at supporting improved manufacturing technologies and processes that allow for a more effective, less expensive, easier to scale up, more sustainable and cleaner production of medicines in the Union. Innovations developed under this action should be designed to enable rapid scale-up of Union pharmaceutical production in the context of a health emergency or to prevent critical shortages of critical medicines. This action supports the Union’s pharmaceutical industry to be better able to respond to public health needs in the context of health emergencies and critical medicines shortages.

It does so by enabling the development of tools that contribute to the improvement and optimisation of manufacturing of medicines, with the objective of reducing production costs (e.g., related to labour and energy consumption), and facilitating compliance with the Union’s environmental occupational and social requirements, as well as the Union’s current and future needs to scale-up pharmaceutical production. This action supports the policy priority to enhance crisis preparedness and response for future health emergencies in relation to medical countermeasures with an all-threats approach, as well as preventing critical shortages of critical medicines, especially those in a situation of technological vulnerability with regards to the EU market. It implements the EU4Health Programme’s general objective of improving the availability, accessibility and affordability of crisis-relevant products (Article 3, point (c) of Regulation (EU) 2021/522) through the specific objectives defined in Article 4, points (b) and (c), of Regulation (EU) 2021/522.

Scope:

This action covers activities aimed at developing support for or innovations targeting the manufacturing of APIs, their intermediates and/or excipients, namely by developing:

a) novel manufacturing processes and technologies, e.g., additive manufacturing, continuous manufacturing and flow chemistry, and biomanufacturing technologies; combined or not with activities covering:

b) novel industrial manufacturing and facility designs, e.g., modular manufacturing, smart manufacturing execution systems, including automation and robotics, advanced analytics, and smart sensors, among other.

Overall, the action should contribute to increasingly sophisticated enhancements to chemical and/or biological processes or decreasing the production of polluting agents. This action is limited to manufacturing technologies and processes and does not cover innovation exclusively targeting the field of quality control.

Expected Impact:

This action is expected to result in:

a) more agile, simplified scale-up, sustainable and resilient manufacturing of APIs, their intermediates, finished products and/or excipients, allowing for better capacity to respond to demand surges and prevent critical shortages of critical medicines.

b) improved competitiveness of the Union’s manufacturing industry, improved Union’s strategic autonomy and more resilient Union’s industry in the field of medical countermeasures/medicines.

基金资源
Purdue Grant Writing Lab: Introduction to Grant Writing	打开链接
University of Wisconsin Writing Center: Planning and Writing a Grant Proposal	打开链接